Literature DB >> 20826636

Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain.

R Cisterna1, G Ezpeleta, O Telleria, J Guinea, B Regueiro, J Garcia-Rodríguez, J Esperalba.   

Abstract

Candidemia studies have documented geographic differences in rates and epidemiology, underscoring the need for surveillance to monitor trends. We conducted prospective candidemia surveillance in Spain to assess the incidence, species distribution, frequency of antifungal resistance, and risk factors for acquiring a Candida infection. Prospective laboratory-based surveillance was conducted from June 2008 to June 2009 in 40 medical centers located around the country. A case of candidemia was defined as the isolation of a Candida species from a blood culture. Incidence rates were calculated per 1,000 admissions. Antifungal susceptibility tests were performed by using broth microdilution assay according to the guidelines of the Clinical and Laboratory Standards Institute. We detected 984 cases, for an overall incidence of 1.09 cases per 1,000 admissions. The crude mortality was 20.20%. Candida albicans was the most common species (49.08%), followed by C. parapsilosis (20.73%), C. glabrata (13.61%), and C. tropicalis (10.77%). Overall, decreased susceptibility to fluconazole occurred in 69 (7.01%) incident isolates. Antifungal resistance was rare, and a moderate linear correlation between fluconazole and voriconazole MICs was observed. This is the largest multicenter candidemia study conducted to date and shows the substantial morbidity and mortality of candidemia in Spain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826636      PMCID: PMC3020865          DOI: 10.1128/JCM.00920-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  44 in total

1.  High rate of non-albicans candidemia in Brazilian tertiary care hospitals.

Authors:  A L Colombo; M Nucci; R Salomão; M L Branchini; R Richtmann; A Derossi; S B Wey
Journal:  Diagn Microbiol Infect Dis       Date:  1999-08       Impact factor: 2.803

2.  Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.

Authors:  M H Nguyen; C J Clancy; V L Yu; Y C Yu; A J Morris; D R Snydman; D A Sutton; M G Rinaldi
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

3.  Emergence of Candida parapsilosis as the predominant species causing candidemia in children.

Authors:  I Levy; L G Rubin; S Vasishtha; V Tucci; S K Sood
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

4.  Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains.

Authors:  C Girmenia; P Martino; F De Bernardis; G Gentile; M Boccanera; M Monaco; G Antonucci; A Cassone
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

5.  The epidemiology of candidemia in two United States cities: results of a population-based active surveillance.

Authors:  A S Kao; M E Brandt; W R Pruitt; L A Conn; B A Perkins; D S Stephens; W S Baughman; A L Reingold; G A Rothrock; M A Pfaller; R W Pinner; R A Hajjeh
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

6.  Candidemia in a Brazilian tertiary care hospital: species distribution and antifungal susceptibility patterns.

Authors:  Ana Graciela Ventura Antunes; Alessandro Comarú Pasqualotto; María Cristina Diaz; Pedro Alves d'Azevedo; Luiz Carlos Severo
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2004-10-22       Impact factor: 1.846

7.  Risk factors for death in patients with candidemia.

Authors:  M Nucci; A L Colombo; F Silveira; R Richtmann; R Salomão; M L Branchini; N Spector
Journal:  Infect Control Hosp Epidemiol       Date:  1998-11       Impact factor: 3.254

8.  Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths.

Authors:  D Pittet; R P Wenzel
Journal:  Arch Intern Med       Date:  1995-06-12

9.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

10.  Constant low rate of fungemia in norway, 1991 to 1996. The Norwegian Yeast Study Group.

Authors:  P Sandven; L Bevanger; A Digranes; P Gaustad; H H Haukland; M Steinbakk
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

View more
  24 in total

1.  Why should the journal of clinical microbiology apologize for publishing a paper plagiarized from its archives?

Authors:  M Jacques Nsuami; Nsanga Besa; Yanyi K Djamba; Emmanuel Sikabwe; Wato Nsa; Gary V Doern
Journal:  J Clin Microbiol       Date:  2011-08       Impact factor: 5.948

2.  Six-year trend analysis of nosocomial candidemia and risk factors in two intensive care hospitals in Mato Grosso, midwest region of Brazil.

Authors:  Hugo Dias Hoffmann-Santos; Claudete Rodrigues Paula; Ana Caroline Akeme Yamamoto; Tomoko Tadano; Rosane C Hahn
Journal:  Mycopathologia       Date:  2013-10-11       Impact factor: 2.574

Review 3.  Insights into Candida tropicalis nosocomial infections and virulence factors.

Authors:  M Negri; S Silva; M Henriques; R Oliveira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-30       Impact factor: 3.267

4.  Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia.

Authors:  Maiken Cavling Arendrup; Sofia Sulim; Anette Holm; Lene Nielsen; Susanne Dam Nielsen; Jenny Dahl Knudsen; Niels Erik Drenck; Jens Jørgen Christensen; Helle Krogh Johansen
Journal:  J Clin Microbiol       Date:  2011-06-29       Impact factor: 5.948

5.  Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots.

Authors:  Maiken Cavling Arendrup; Juan-Luis Rodriguez-Tudela; Steven Park; Guillermo Garcia-Effron; Guillaume Delmas; Manuel Cuenca-Estrella; Alicia Gomez-Lopez; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

6.  Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain.

Authors:  Matteo Bassetti; Maria Merelli; Elda Righi; Ana Diaz-Martin; Eva Maria Rosello; Roberto Luzzati; Anna Parra; Enrico Maria Trecarichi; Maurizio Sanguinetti; Brunella Posteraro; Jose Garnacho-Montero; Assunta Sartor; Jordi Rello; Mario Tumbarello
Journal:  J Clin Microbiol       Date:  2013-10-09       Impact factor: 5.948

7.  Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014.

Authors:  Francesco Barchiesi; Elena Orsetti; Rosaria Gesuita; Edlira Skrami; Esther Manso
Journal:  Infection       Date:  2015-09-26       Impact factor: 3.553

8.  A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade.

Authors:  A M Tortorano; A Prigitano; C Lazzarini; M Passera; M L Deiana; S Cavinato; C De Luca; A Grancini; G Lo Cascio; C Ossi; E Sala; M T Montagna
Journal:  Infection       Date:  2013-04-05       Impact factor: 3.553

9.  Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital.

Authors:  Guillermo Garcia-Effron; Emilia Canton; Javier Pemán; Amanda Dilger; Eva Romá; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2012-08-06       Impact factor: 5.790

10.  Identification and differentiation of Candida parapsilosis complex species by use of exon-primed intron-crossing PCR.

Authors:  Xiaobo Feng; Zengbin Wu; Bo Ling; Shuming Pan; Wanqing Liao; Weihua Pan; Zhirong Yao
Journal:  J Clin Microbiol       Date:  2014-03-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.